MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Drug therapy for exercise-induced arrhythmias

Back to heart watch blog Blogs list Cancer blog  


Subscribe To Heart Watch Blog RSS Feed  RSS content feed What is RSS feed?

Drug therapy for exercise-induced arrhythmias




A 12-year-old Dutch boy bedridden for three years because of an inherited cardiac arrhythmia syndrome can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

The investigators, led by Bjrn Knollmann, M.D., Ph.D., report this week in Nature Medicine that the clinically available drug flecainide prevents potentially lethal arrhythmias in patients with a specific type of exercise or stress-induced arrhythmia disorder called CPVT.

"It's potentially a breakthrough in the therapy of this rare syndrome," said Knollmann, associate professor of Medicine and Pharmacology.



Drug therapy for exercise-induced arrhythmias

Patients with CPVT experience abnormally rapid heart rates (tachycardia), commonly during exercise or stress, and are at risk for fainting and cardiac arrest. The syndrome kills up to 50 percent of untreated patients, and it may account for some unexplained sudden cardiac deaths in young athletes.

Current therapy has been limited to two medications beta blockers, often used at very high doses, and calcium channel blockers to control the arrhythmias. Implantable cardioverter defibrillators (ICDs) are placed in patients at high risk for sudden death, but ongoing arrhythmias can result in frequent stressful shocks.

The Dutch patient, for example, experienced ventricular tachycardia and ICD shocks whenever he got out of bed, Knollmann said.

Defibrillator treatment also can be problematic for pediatric patients (CPVT is commonly diagnosed in children), who require multiple surgical revisions of their systems.

"For this particular disease, the ICD is a suboptimal therapy," he said. "It's extremely desirable to have a drug therapy that reduces or prevents the ventricular tachycardias, and therefore prevents the ICD shocks".

Knollmann and his team have been studying the molecular defects that trigger arrhythmias. They knew that mutations in two genes that encode calcium-handling proteins, the ryanodine receptor and calsequestrin, cause the disorder.

In 2006, the group discovered how these mutations cause arrhythmias at the cellular level by allowing calcium to "leak" out of its storage containers inside heart cells. Knollmann's team developed a mouse model for CPVT (by eliminating the calsequestrin gene) and proposed using the model to study medications and interventions for the disorder.

They tried flecainide, a clinically available anti-arrhythmic that is used to treat atrial fibrillation. It worked.

In isolated heart cells, flecainide blocked the ryanodine receptor and the calcium "leak" (the underlying molecular defect in CPVT), and it completely prevented ventricular arrhythmias in the mouse model of CPVT.

"So we knew that this established drug specifically targets the disease mechanism in CPVT," Knollmann said.

With these encouraging results, the researchers teamed with Arthur Wilde, M.D., Ph.D., at the University of Amsterdam, to test flecainide in two patients with CPVT who continued to have arrhythmias while on conventional therapies the previously mentioned 12-year-old boy and a 36-year-old woman. The boy has a mutation in the calsequestrin gene, the same gene mutated in the mouse model; the woman has a mutation in the ryanodine receptor, which is more common among CPVT patients.

In both patients, flecainide (combined with a beta blocker in the boy) prevented exercise-induced ventricular arrhythmias. The patients have taken flecainide for more than six months now and are living normal lives.

The group is currently enrolling additional CPVT patients to clearly define the benefits and risks of flecainide and to compare how it works in patients who have varying ryanodine receptor and calsequestrin mutations.

Frank Fish, M.D., a pediatric heart specialist at Vanderbilt, has placed two patients with CPVT on flecainide treatment.

"We're hoping that flecainide is going to allow us to back off the excessively high doses of beta blockers, limit defibrillator discharges in patients with ICDs, and decrease the likelihood that we'll need to implant defibrillators in these patients at a young age if the arrhythmias can be controlled medically," Fish said. "That's an exciting prospect".

Fish feels like he's come full circle with flecainide. In the late 1980s, he surveyed the drug's effects in pediatric patients as a follow-up to a large clinical trial in adults that showed increased rates of death among heart attack survivors who had ventricular arrhythmias. Fish and colleagues found an unexpectedly high frequency of pro-arrhythmia among young patients.

"So for 20 years, physicians have been reluctant to use flecainide for ventricular arrhythmias," Fish said. "It's interesting to now find ourselves turning to a medicine we've been fearful of using. In this specific population (CPVT patients), it may turn out to be the magic bullet".


Posted by: Daniel    Source




Did you know?
A 12-year-old Dutch boy bedridden for three years because of an inherited cardiac arrhythmia syndrome can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers. The investigators, led by Bjrn Knollmann, M.D., Ph.D., report this week in Nature Medicine that the clinically available drug flecainide prevents potentially lethal arrhythmias in patients with a specific type of exercise or stress-induced arrhythmia disorder called CPVT.

Medicineworld.org: Drug therapy for exercise-induced arrhythmias

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.